Inclusion Criteria:

- Patients must have signed a written informed consent form prior to any study specific
screening procedures

- 18 years or older

- KPS ≥ 50%

- Histologically confirmed adenocarcinoma of the lung

- Activating mutation of EGFR

- Newly diagnosed CNS metastasis or in progression with at least one measurable lesion
in the brain (defined as any lesion > 1 cm on T1-weighted contrast enhanced MRI)

- Patients could enter the study regardless of previous treatment (included
chemotherapy) for metastatic extracranial disease, except TKI.

- No steroids or stable or decreasing dose of steroids for at least 5 days before the
MRI evaluation.

- Adequate hematologic, liver and renal functions: neutrophil count ≥ 1.5 x 109/L;
platelets ≥ 100 x 109/L; Hb ≥ 9 g/Dl; Total bilirubin < 1.5 x ULN; AST or ALT < 2.5
x ULN (< 5 x ULN in patients with liver metastases); Serum creatinine ≤ 1.5 x ULN or
Creatinine clearance ≥ 50 mL/min

Exclusion Criteria:

- Prior treatment of brain metastases with WBRT or TKI

- Patient eligible for radiosurgery or surgical resection

- Contre indication at the radiotherapy

- Leptomeningeal disease

- Previous history of cancer (other than curatively treated basal and squamous cell
carcinoma of the skin and/or in-situ carcinoma of the cervix) within the the 5 years
before study entry

- Prior treatment with Gefitinib or other TKI

- Pregnant or breast feeding women

- Women with an intact uterus (unless amenorrhoeic for the last 24 months) not using
effective means of contraception